Asthma affects nearly 25 million Americans, with many patients having an uncontrolled condition and at risk of severe exacerbations leading to hospitalization.[1] The modern approach to asthma treatment has shifted from reactive treatment with only rescue inhalers to a preventive model aimed at preventing attacks.[1] The SMART regimen (Single Maintenance and Reliever Therapy) has become the gold standard, which combines a steroid and a fast-acting bronchodilator in one inhaler, which also treats underlying airway inflammation.[1] For patients with severe asthma, ultra-long-acting biologics are available that target specific immune pathways such as IL-5 or TSLP and significantly reduce hospitalizations.[1] In advanced stages of trials, mRNA vaccines are designed to teach the immune system to ignore common allergens like pollen.[1] For patients with severe, drug-resistant asthma, bronchial thermoplasty—a procedure that uses controlled heat to reduce excessive smooth muscle in the airways—remains available.[1]